Samyang Biopharmaceuticals Corporation, a biomedical affiliate of Samyang Group, is pressing ahead to build the global footing for the thread lift brand, “Croquis,” with evidence-based marketing. The name, “Croquis,” comes from a drawing technique of the same name through which artists quickly sketch the outline of a model. As the name of the company, it carries the meaning that the thread lifts the facial outlines quickly and naturally.

Last year, Samyang Biopharmaceuticals Corporation successfully developed Croquis, received a CE mark which is necessary to enter the EU market, and began to target the global market. Last month, the company also successfully made its first debut in IMCAS World Congress 2020, one of the world’s largest congresses on aesthetic medicine. Throughout the course of the congress, 900 participants from 81 countries visited the booth set up by Samyang Biopharmaceuticals Corporation, 100 of which received consultation. Currently, the company is discussing specific conditions with distributors in the UK, France, and Russia.

Samyang Biopharmaceuticals Corporation overcame disadvantages as a late comer in data-oriented and evidence-based marketing and is earning trust in the international aesthetic medicine market. While traditional aesthetic thread brands only compare and emphasize preoperative and postoperative effects, Samyang Biopharmaceuticals Corporation aims towards evidence-based marketing, putting in efforts to obtain data about not only operative effects by part of the face but also the thread’s physical properties.

Currently, Samyang Biopharmaceuticals Corporation is conducting a study with dermatologists and plastic surgeons in the US, France, and Spain with the goal of obtaining data on the thread’s physical properties, including the thread’s elasticity and strength, to reaffirm Croquis’s safety and efficacy and to produce optimal effects for each part of the face. The interim study results will be presented to physicians around the world at global conferences including Aesthetic & Anti-aging Medicine World Congress.

An official from Samyang Biopharmaceuticals Corporation said, “The aesthetic medicine business of Samyang Biopharmaceuticals Corporation is aiming towards producing art technology, which represents the convergence between art and technology. Based on the technologies Samyang Biopharmaceuticals Corporation has built, we will materialize natural beauty.”

Meanwhile, Samyang Biopharmaceuticals Corporation is conducting a clinical trial on the biodegradable polymer polycaprolactone (PCL) filler in Korea for its launch next year. Samyang Biopharmaceuticals Corporation expects that while the mainstream products containing hyaluronic acid (HA) demonstrate effects for 6 months, the PCL filler can remain effective for up to 24 months. The company aims to improve volume retention and safety compared to other existing products.​